Last reviewed · How we verify
MDX2001
At a glance
| Generic name | MDX2001 |
|---|---|
| Sponsor | ModeX Therapeutics, An OPKO Health Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDX2001 CI brief — competitive landscape report
- MDX2001 updates RSS · CI watch RSS
- ModeX Therapeutics, An OPKO Health Company portfolio CI